PTAB

The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co (NYSE: LLY) Thursday in an inter partes review of the ’209 patent for Alimta, a chemotherapy drug for lung cancer. “Based on the record before us, we conclude that petitioner has failed to demonstrate by a...

On August 24, the Patent Trial and Appeal Board (PTAB) invalidated Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) ‘250 and ‘450 mg/mL Copaxone patents. This week, the PTAB invalidated the remaining ‘302 patent as well. Where do these PTAB decisions leave investors?...